

IN THE CLAIMS

Delete claims 1-4, 150-154, 156-173, 179-182, 187-191, 196-200 and 205-209.

Please amend claims 155, 174-177, 183-186, 192-195 and 201-204 as follows:

155 (Amended). The therapeutic composition of any one of claims 174-177, wherein said beta-amyloid is human beta-amyloid.

161 (Amended). The therapeutic composition of any one of claims 183-186, wherein said beta-amyloid is human beta-amyloid.

167 (Amended). The therapeutic composition of any one of claims 192-195, wherein said beta-amyloid is human beta-amyloid.

173 (Amended). The therapeutic composition of any one of claims 201-204, wherein said beta-amyloid is human beta-amyloid.

174 (Amended). A therapeutic composition, comprising:

a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a monoclonal antibody or antigen binding fragment thereof, said monoclonal antibody being a human monoclonal antibody or a genetically-engineered monoclonal antibody, wherein

(i) said antibody and said fragment recognize an epitope within residues 1-28 of beta-amyloid, and

(ii) said antibody and said fragment inhibit aggregation of beta-amyloid.

175 (Amended). The therapeutic composition of claim 174, wherein said pharmaceutical formulation comprises a pharmaceutically acceptable carrier and a human monoclonal antibody.

176 (Amended). The therapeutic composition of claim 174, wherein said pharmaceutical formulation comprises a pharmaceutically acceptable carrier and a genetically-engineered monoclonal antibody.

177 (Amended). The therapeutic composition of claim 176, wherein said genetically-engineered monoclonal antibody is a single-chain antibody.

183 (Amended). A therapeutic composition, comprising:

a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a monoclonal antibody or antigen binding fragment thereof, said monoclonal antibody being a human monoclonal antibody or a genetically-engineered monoclonal antibody, wherein

(i) said antibody is obtainable using residues 1-28 of beta-amyloid as an immunogen, and

(ii) said antibody and said fragment inhibit aggregation of beta-amyloid.

184 (Amended). The therapeutic composition of claim 183, wherein said pharmaceutical formulation comprises a

pharmaceutically acceptable carrier and a human monoclonal antibody.

185 (Amended). The therapeutic composition of claim 183, wherein said pharmaceutical formulation comprises a pharmaceutically acceptable carrier and a genetically-engineered monoclonal antibody.

186 (Amended). The therapeutic composition of claim 185, wherein said genetically-engineered monoclonal antibody is a single-chain antibody.

192 (Amended). A therapeutic composition, comprising:

a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a monoclonal antibody or antigen binding fragment thereof, said monoclonal antibody being a human monoclonal antibody or a genetically-engineered monoclonal antibody, wherein

(i) said antibody and said fragment recognize an epitope within residues 1-28 of beta-amyloid, and

(ii) said antibody and said fragment maintain the solubility of soluble beta-amyloid.

193 (Amended). The therapeutic composition of claim 192, wherein said pharmaceutical formulation comprises a pharmaceutically acceptable carrier and a human monoclonal antibody.

194 (Amended). The therapeutic composition of claim 192, wherein said pharmaceutical formulation comprises a

pharmaceutically acceptable carrier and a genetically-engineered monoclonal antibody.

195 (Amended). The therapeutic composition of claim 194, wherein said genetically-engineered monoclonal antibody is a single-chain antibody.

201 (Amended). A therapeutic composition, comprising:

a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a monoclonal antibody or antigen binding fragment thereof, said monoclonal antibody being a human monoclonal antibody or a genetically-engineered monoclonal antibody, wherein

(i) said antibody is obtainable using residues 1-28 of beta-amyloid as an immunogen, and

(ii) said antibody and said fragment maintain the solubility of soluble beta-amyloid.

202 (Amended). The therapeutic composition of claim 201, wherein said pharmaceutical formulation comprises a pharmaceutically acceptable carrier and a human monoclonal antibody.

203 (Amended). The therapeutic composition of claim 201, wherein said pharmaceutical formulation comprises a pharmaceutically acceptable carrier and a genetically-engineered monoclonal antibody.

204 (Amended). The therapeutic composition of claim 203, wherein said genetically-engineered monoclonal antibody is a single-chain antibody.

Statements under 37 C.F.R. §1.173(c)

The following statements are made pursuant to the requirements of 37 C.F.R. §1.173(c). Patent claims 1-4 have been cancelled without prejudice toward the continuation of prosecution in a continuing application. Added claims 5-154, 156-160, 162-166, 168-172, 178-182, 187-191, 196-200 and 205-209 have also been cancelled without prejudice. Claims 155, 161, 167, 173-177, 183-186, 192-195 and 201-204 are the only claims now pending in the case.

Pursuant to 37 C.F.R. §1.173(c), the following is an explanation of the support of the disclosure of the patent for the changes made to the claims by the present amendment.

Each of claims 174, 183, 192 and 201 has been amended to move the term "pharmaceutical formulation" from the preamble to the body of the claim and to use the term "therapeutic composition" in the preamble. This is supported, for example, at column 6, lines 1-6, particularly line 4, where it provides that the antibodies may be used "therapeutically." This disclosure, read in combination with the disclosure at column 9, lines 20-32, establishes that the monoclonal antibody may be used therapeutically as a pharmaceutical formulation that includes the monoclonal antibody with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. This therapeutic formulation is implicitly "a therapeutic composition" and thus this term is sufficiently supported by the specification as a whole.

Appln. No. 09/441,140
Amendment dated January 17, 2006
Reply to Office action of July 29, 2005

The only other change to each of claims 174, 183, 192 and 201 is to move the paragraph (B) "a pharmaceutically acceptable carrier" into the first paragraph after the preamble. The letters "(A)" and "(B)" have been deleted, but this is not a substantive change to the claim. Thus, the changes to each of claims 174, 183, 192 and 201 are fully supported by the present specification.

All of the dependent claims have been amended to change "pharmaceutical formulation" to "therapeutic composition" in the preamble. This is not new matter for the same reason as discussed above with respect to the substitution of "therapeutic composition" for "pharmaceutical formulation" in the preamble of the independent claims.

As to claims 175, 176, 184, 185, 193, 194, 202 and 203, the wording has been revised to clarify that the formulation comprises the carrier and either a human monoclonal antibody (for claims 175, 184, 193 and 202) or a genetically-engineered monoclonal antibody (for claims 176, 185, 194 and 203). The previous language could have been ambiguous as to whether or not fragments were included in the scope of these dependent claims. The new language clarifies that they are not. This is a change of style, but not substance. Thus, these claims are supported for the same reasons that they have been found to be supported prior to this amendment.

Similarly, with respect to claims 177, 186, 195 and 204, the insertion of the term "genetically-engineered

Appln. No. 09/441,140
Amendment dated January 17, 2006
Reply to Office action of July 29, 2005

monoclonal" is a change, but is merely using words of the claim from which each depends in order to clarify the antecedent basis. No new terminology is used, and this is, thus, supported for the same reasons that it has already been found to be supported in the claims from which they depend.

Except for the preamble, the only change to claims 155, 161, 167 and 173 is that each has been made dependent from a corresponding set of claims that do not include "unit dosage." Thus, each is still supported for the same reasons that it was supported prior to this amendment.